

Case Series Drug Analysis Print

Name: FOI 21/740 Seqirus

Report Run Date: 09-Jul-2021

Data Lock Date: 08-Jul-2021 18:30:03

Earliest Reaction Date: 29-Sep-2016

MedDRA Version: MedDRA 24.0

FOI 21/740 Seqirus: All spontaneous UK suspected adverse drug reaction reports associated with Seqirus up to and including the 08/07/2021

Case Series Drug Analysis Print

Name: FOI 21/740 Seqirus

Report Run Date: 09-Jul-2021
Earliest Reaction Date: 29-Sep-2016

Data Lock Date: 08-Jul-2021 18:30:03
MedDRA Version: MedDRA 24.0

Reaction Name	Total	Fatal
Cardiac disorders		
<i>Ventricular arrhythmias and cardiac arrest</i>		
Cardiac arrest	1	1
Cardiac disorders SOC TOTAL	1	1

Case Series Drug Analysis Print

Name: FOI 21/740 Seqirus

Report Run Date: 09-Jul-2021
Earliest Reaction Date: 29-Sep-2016

Data Lock Date: 08-Jul-2021 18:30:03
MedDRA Version: MedDRA 24.0

Reaction Name	Total	Fatal
Ear disorders		
<i>Inner ear signs and symptoms</i>		
Vertigo	1	0
Ear disorders SOC TOTAL	1	0

Case Series Drug Analysis Print

Name: FOI 21/740 Seqirus

Report Run Date: 09-Jul-2021
Earliest Reaction Date: 29-Sep-2016

Data Lock Date: 08-Jul-2021 18:30:03
MedDRA Version: MedDRA 24.0

Reaction Name	Total	Fatal
Eye disorders		
<i>Visual impairment and blindness (excl colour blindness)</i>		
Blindness	1	0
Blindness transient	1	0
Visual impairment	1	0
Eye disorders SOC TOTAL	3	0

Case Series Drug Analysis Print

Name: FOI 21/740 Seqirus

Report Run Date: 09-Jul-2021
Earliest Reaction Date: 29-Sep-2016

Data Lock Date: 08-Jul-2021 18:30:03
MedDRA Version: MedDRA 24.0

Reaction Name	Total	Fatal
Gastrointestinal disorders		
<i>Gastrointestinal and abdominal pains (excl oral and throat)</i>		
Abdominal pain	1	0
<i>Intestinal haemorrhages</i>		
Rectal haemorrhage	1	0
<i>Nausea and vomiting symptoms</i>		
Nausea	2	0
Vomiting	1	0
Vomiting projectile	1	0
<i>Oral soft tissue signs and symptoms</i>		
Lip erythema	1	0
Paraesthesia oral	1	0
<i>Oral soft tissue swelling and oedema</i>		
Lip swelling	1	0
Gastrointestinal disorders SOC TOTAL	9	0

Case Series Drug Analysis Print

Name: FOI 21/740 Seqirus

Report Run Date: 09-Jul-2021
Earliest Reaction Date: 29-Sep-2016

Data Lock Date: 08-Jul-2021 18:30:03
MedDRA Version: MedDRA 24.0

Reaction Name	Total	Fatal
General disorders		
<i>Asthenic conditions</i>		
Fatigue	2	0
Malaise	3	0
<i>Febrile disorders</i>		
Pyrexia	6	0
<i>Feelings and sensations NEC</i>		
Chills	2	0
Feeling cold	1	0
Feeling hot	2	0
<i>General signs and symptoms NEC</i>		
Influenza like illness	2	0
Peripheral swelling	1	0
Swelling	1	0
Swelling face	1	0
<i>Injection site reactions</i>		
Injected limb mobility decreased	1	0
Injection site pain	2	0
<i>Oedema NEC</i>		
Face oedema	1	0
<i>Pain and discomfort NEC</i>		
Chest discomfort	1	0
Pain	2	0
<i>Vaccination site reactions</i>		
Vaccination site erythema	3	0
Vaccination site mass	1	0
Vaccination site pain	5	0
Vaccination site swelling	4	0
Vaccination site warmth	1	0
General disorders SOC TOTAL	42	0

Case Series Drug Analysis Print

Name: FOI 21/740 Seqirus

Report Run Date: 09-Jul-2021
Earliest Reaction Date: 29-Sep-2016

Data Lock Date: 08-Jul-2021 18:30:03
MedDRA Version: MedDRA 24.0

Reaction Name	Total	Fatal
Immune system disorders		
<i>Allergic conditions NEC</i>		
Hypersensitivity	3	0
<i>Anaphylactic and anaphylactoid responses</i>		
Anaphylactic reaction	1	0
Immune system disorders SOC TOTAL	4	0

Case Series Drug Analysis Print

Name: FOI 21/740 Seqirus

Report Run Date: 09-Jul-2021
Earliest Reaction Date: 29-Sep-2016

Data Lock Date: 08-Jul-2021 18:30:03
MedDRA Version: MedDRA 24.0

Reaction Name	Total	Fatal
Infections		
<i>Herpes viral infections</i>		
Herpes zoster	1	0
<i>Upper respiratory tract infections</i>		
Nasopharyngitis	1	0
Sinusitis	1	0
Infections SOC TOTAL	3	0

Case Series Drug Analysis Print

Name: FOI 21/740 Seqirus

Report Run Date: 09-Jul-2021
Earliest Reaction Date: 29-Sep-2016

Data Lock Date: 08-Jul-2021 18:30:03
MedDRA Version: MedDRA 24.0

Reaction Name	Total	Fatal
Injuries		
<i>Muscle, tendon and ligament injuries</i>		
Muscle injury	1	0
Injuries SOC TOTAL	1	0

Case Series Drug Analysis Print

Name: FOI 21/740 Seqirus

Report Run Date: 09-Jul-2021
Earliest Reaction Date: 29-Sep-2016

Data Lock Date: 08-Jul-2021 18:30:03
MedDRA Version: MedDRA 24.0

Reaction Name	Total	Fatal
Metabolic disorders		
<i>Appetite disorders</i>		
Decreased appetite	1	0
Metabolic disorders SOC TOTAL	1	0

Case Series Drug Analysis Print

Name: FOI 21/740 Seqirus

Report Run Date: 09-Jul-2021
 Earliest Reaction Date: 29-Sep-2016

Data Lock Date: 08-Jul-2021 18:30:03
 MedDRA Version: MedDRA 24.0

Reaction Name	Total	Fatal
Muscle & tissue disorders		
<i>Arthropathies NEC</i>		
Arthritis	1	0
<i>Joint related signs and symptoms</i>		
Arthralgia	4	0
Joint swelling	1	0
<i>Muscle pains</i>		
Myalgia	2	0
<i>Muscle related signs and symptoms NEC</i>		
Muscle atrophy	1	0
Muscle spasms	1	0
<i>Muscle weakness conditions</i>		
Muscular weakness	3	0
<i>Musculoskeletal and connective tissue conditions NEC</i>		
Musculoskeletal stiffness	2	0
<i>Musculoskeletal and connective tissue pain and discomfort</i>		
Pain in extremity	8	0
Muscle & tissue disorders SOC TOTAL	23	0

Case Series Drug Analysis Print

Name: FOI 21/740 Seqirus

Report Run Date: 09-Jul-2021
Earliest Reaction Date: 29-Sep-2016

Data Lock Date: 08-Jul-2021 18:30:03
MedDRA Version: MedDRA 24.0

Reaction Name	Total	Fatal
Neoplasms		
<i>Leiomyosarcomas</i>		
Leiomyosarcoma	1	0
Neoplasms SOC TOTAL	1	0

Case Series Drug Analysis Print

Name: FOI 21/740 Seqirus

Report Run Date: 09-Jul-2021
Earliest Reaction Date: 29-Sep-2016

Data Lock Date: 08-Jul-2021 18:30:03
MedDRA Version: MedDRA 24.0

Reaction Name	Total	Fatal
Nervous system disorders		
<i>Abnormal sleep-related events</i>		
Sleep paralysis	1	0
<i>Coordination and balance disturbances</i>		
Ataxia	1	0
<i>Disturbances in consciousness NEC</i>		
Lethargy	1	0
Syncope	4	0
<i>Headaches NEC</i>		
Headache	1	0
<i>Neurologic visual problems NEC</i>		
Tunnel vision	1	0
<i>Neurological signs and symptoms NEC</i>		
Dizziness	3	0
<i>Paraesthesias and dysaesthesias</i>		
Burning sensation	1	0
Hypoaesthesia	1	0
Paraesthesia	2	0
<i>Seizures and seizure disorders NEC</i>		
Seizure	2	0
<i>Speech and language abnormalities</i>		
Dysarthria	1	0
Nervous system disorders SOC TOTAL	19	0

Case Series Drug Analysis Print

Name: FOI 21/740 Seqirus

Report Run Date: 09-Jul-2021
Earliest Reaction Date: 29-Sep-2016

Data Lock Date: 08-Jul-2021 18:30:03
MedDRA Version: MedDRA 24.0

Reaction Name	Total	Fatal
Psychiatric disorders		
<i>Confusion and disorientation</i>		
Disorientation	1	0
<i>Hallucinations (excl sleep-related)</i>		
Hallucination	1	0
<i>Parasomnias</i>		
Nightmare	1	0
<i>Sleep disorders NEC</i>		
Sleep disorder	1	0
Psychiatric disorders SOC TOTAL	4	0

Case Series Drug Analysis Print

Name: FOI 21/740 Seqirus

Report Run Date: 09-Jul-2021
Earliest Reaction Date: 29-Sep-2016

Data Lock Date: 08-Jul-2021 18:30:03
MedDRA Version: MedDRA 24.0

Reaction Name	Total	Fatal
Respiratory disorders		
<i>Breathing abnormalities</i>		
Dyspnoea	2	0
<i>Coughing and associated symptoms</i>		
Cough	1	0
<i>Upper respiratory tract signs and symptoms</i>		
Rhinorrhoea	1	0
Respiratory disorders SOC TOTAL	4	0

Case Series Drug Analysis Print

Name: FOI 21/740 Seqirus

Report Run Date: 09-Jul-2021
 Earliest Reaction Date: 29-Sep-2016

Data Lock Date: 08-Jul-2021 18:30:03
 MedDRA Version: MedDRA 24.0

Reaction Name	Total	Fatal
Skin disorders		
<i>Apocrine and eccrine gland disorders</i>		
Hyperhidrosis	3	0
<i>Dermatitis ascribed to specific agent</i>		
Drug eruption	1	0
<i>Erythemas</i>		
Erythema	7	0
<i>Pruritus NEC</i>		
Pruritus	4	0
<i>Purpura and related conditions</i>		
Purpura	1	0
<i>Rashes, eruptions and exanthems NEC</i>		
Rash	3	0
Rash erythematous	1	0
Rash papular	1	0
Rash pruritic	2	0
<i>Urticarias</i>		
Urticaria	3	0
Skin disorders SOC TOTAL	26	0

Case Series Drug Analysis Print

Name: FOI 21/740 Seqirus

Report Run Date: 09-Jul-2021
Earliest Reaction Date: 29-Sep-2016

Data Lock Date: 08-Jul-2021 18:30:03
MedDRA Version: MedDRA 24.0

Reaction Name	Total	Fatal
Vascular disorders		
<i>Site specific vascular disorders NEC</i>		
Pallor	1	0
<i>Vasculitides NEC</i>		
Vasculitis	1	0
Vascular disorders SOC TOTAL	2	0
TOTAL REACTIONS FOR DRUG	144	1
TOTAL REPORTS	52	
TOTAL FATAL OUTCOME REPORTS		1